MediciNova
Price & Volume
Stats
See moreOpen | $1.39 |
Previous Close | $1.42 |
Day Range | $1.38-$1.40 |
52W Range | $1.13-$1.96 |
Market Cap | $69.4M |
Shares Short | 193,563 |
Financials
See moreRevenue (12 Mos) | $409,657 |
Revenue Growth (YoY) | 0% |
Gross Profit (12 Mos) | $31,051 |
Diluted EPS | -$0.24 |
News
See moreYahoo Finance • 3 months ago
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
Yahoo Finance • 3 months ago
MediciNova Announces Update and Basic Characteristic Randomized Patients’ of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND
Yahoo Finance • 4 months ago
MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor
Yahoo Finance • 4 months ago
MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards
About
CEO | Dr. Yuichi Iwaki M.D., Ph.D. |
Address | 4275 Executive Square, La Jolla, CA, United States, 92037 |
Sector | Healthcare |
Industry | Biotechnology |
Full-Time Employees | 13 |
